Want To Milk A Cash Cow? Try Pediatric Exclusivity

1 Comment

cowWhen drugmakers look to milk their existing cash cows just a little more, what’s the best strategy? Although pediatric exclusivity can certainly boost cash flow, tinkering with a drug’s underlying science may actually yield more long-term value, according to a report by Cutting Edge Information, which queried 28 drugmakers as part of its study.

What the industry likes to call life cycle management can be pursued through different means, of course. And this includes pediatric exclusivity, new indications, new formulations, patent retention, next generation versions, authorized generics or a form of strategic pricing. But each approach comes with a price. For instance, four of the strategies require clinical trials.

cutting-edge-plmgmt-strategiesAs the chart indicates, pediatric exclusivity is the most profitable - earning $130 for each $1 spent - and requires relatively small trials for an additional six months of market exclusivity. For the biggest sellers, of course, those six months can be worth huge amounts of money. One exec confessed his company once gained pediatric exclusivity with just 10 days left before the patent expired, but that was worth an an extra $550 million in sales.

Nonetheless, drugmakers often lack the time to complete such trials. And when trials yield unanticipated shortcomings, brand teams may have less time to come up with back-up plans. One the other hand, new indications, different formulations and next-generation versions take longer to execute than pediatric exclusivity.

Yet while their return on income is not as high as pediatric exclusivity, the increase in net revenue can exceed other options. Moreover, new formulations or next-generation products can presumably offer financial gains that last longer than pediatric exclusivity. For those cannot see the chart, the return for new indications was $29.92 for each $1 spent, while new formulations generated $26.20 for every $1 spent. At the other end of the spectrum, authorized generics yielded $10.80 and pricing offered a $10 return for each $1 spent. A next-generation med returned $11.33.

cow thx to jelleS on flickr

Jump to comments

Share

Comments

  1. Informative, i.e., putting a dollar value on each strategy. However, these strategies are not new, they’ve been used for many, many years. Recall, Cardizem, Cardizem SR, Cardizem XL, or Wellbutrin, Wellbutrin SR, and Wellbutrin XL. With the rising cost of health care you have to wonder why the government doesn’t crack down on this stuff. It’s a little more dicey with pediatric exclusivity because the big pharmas don’t have a real good track record of doing pediatric clinical trials because it’s hard to enroll kids. So there may be some benefit if they really do study the drug in kids but what they really do is “confirm” what has been going on in the off-label arena for sometime. So is there really new knowledge being gained? At what cost?

Leave a Comment


6 - four =

Subscribe

RSS Feed

Comments feed for this post only.

Clear

Clear

All rights reserved, UBM Canon. Copyright, UBM Canon.

Thanks for trying out the new Pharmalot printing tools. If you're got any suggestions for how we can help you print better, please let us know by clicking on the contact link at http://www.pharmalot.com/